Your browser is no longer supported. Please, upgrade your browser.
DURECT Corporation
Index- P/E- EPS (ttm)-0.07 Insider Own1.43% Shs Outstand217.54M Perf Week-7.37%
Market Cap391.00M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float206.10M Perf Month-6.38%
Income-14.30M PEG- EPS next Q-0.04 Inst Own49.60% Short Float4.59% Perf Quarter-28.16%
Sales30.70M P/S12.74 EPS this Y40.10% Inst Trans0.30% Short Ratio5.31 Perf Half Y0.57%
Book/sh0.38 P/B4.63 EPS next Y-44.40% ROA- Target Price- Perf Year-18.52%
Cash/sh0.44 P/C4.03 EPS next 5Y15.00% ROE- 52W Range1.52 - 2.96 Perf YTD-14.98%
Dividend- P/FCF- EPS past 5Y17.80% ROI-20.70% 52W High-40.54% Beta1.40
Dividend %- Quick Ratio8.80 Sales past 5Y9.50% Gross Margin95.60% 52W Low15.79% ATR0.09
Employees81 Current Ratio9.00 Sales Q/Q37.50% Oper. Margin- RSI (14)43.40 Volatility6.08% 5.41%
OptionableYes Debt/Eq0.26 EPS Q/Q10.20% Profit Margin- Rel Volume0.20 Prev Close1.72
ShortableYes LT Debt/Eq0.22 EarningsMay 04 AMC Payout- Avg Volume1.78M Price1.76
Recom1.80 SMA20-0.98% SMA50-10.69% SMA200-12.40% Volume351,072 Change2.33%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
May-04-21 07:45PM  
Apr-27-21 08:30AM  
Mar-09-21 09:00AM  
Mar-04-21 05:31PM  
Mar-03-21 06:02PM  
Feb-04-21 09:18AM  
Feb-03-21 04:01PM  
Feb-02-21 08:28AM  
Jan-25-21 08:30AM  
Jan-05-21 08:30AM  
Jan-04-21 08:30AM  
Dec-21-20 08:30AM  
Dec-16-20 08:30AM  
Dec-09-20 01:33PM  
Dec-07-20 11:15AM  
Nov-13-20 09:00AM  
Nov-10-20 08:30AM  
Nov-02-20 11:31PM  
Oct-27-20 08:30AM  
Oct-26-20 04:30PM  
Oct-05-20 08:30AM  
Sep-30-20 04:53PM  
Sep-23-20 08:30AM  
Sep-22-20 08:30AM  
Sep-10-20 08:30AM  
Aug-27-20 08:30AM  
Aug-26-20 04:30PM  
Aug-05-20 03:31PM  
Aug-04-20 01:00AM  
Aug-03-20 06:35PM  
Jul-28-20 08:30AM  
Jul-07-20 07:35AM  
Jul-01-20 08:30AM  
Jun-29-20 09:00AM  
Jun-26-20 05:15PM  
Jun-11-20 02:45PM  
May-28-20 09:00AM  
May-26-20 08:30AM  
May-20-20 10:04AM  
May-12-20 03:00PM  
May-11-20 06:55PM  
May-04-20 05:00PM  
Apr-28-20 12:33PM  
Mar-24-20 04:18PM  
Mar-03-20 04:05PM  
Feb-26-20 07:30AM  
Feb-10-20 08:05AM  
Jan-31-20 11:14AM  
Jan-17-20 08:19AM  
Jan-16-20 02:38PM  
Jan-02-20 05:28PM  
Dec-30-19 09:24AM  
Dec-29-19 09:40PM  
Dec-19-19 05:02PM  
Dec-05-19 03:21PM  
Nov-15-19 08:00AM  
Nov-12-19 08:45AM  
Nov-06-19 05:47PM  
Nov-04-19 04:05PM  
Oct-30-19 08:00AM  
Oct-21-19 10:12AM  
Oct-18-19 10:23AM  
Oct-17-19 04:05PM  
Oct-07-19 08:00AM  
Oct-02-19 08:00AM  
Sep-26-19 08:00AM  
Sep-18-19 07:39AM  
Sep-17-19 08:00AM  
Sep-09-19 09:29AM  
Sep-07-19 12:19PM  
Sep-06-19 12:24PM  
Sep-04-19 08:00AM  
Aug-29-19 04:44PM  
Aug-20-19 10:00AM  
Aug-01-19 04:05PM  
Jul-29-19 10:08AM  
Jul-25-19 04:30PM  
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bleichroeder LP10% OwnerSep 01Sale1.68250,000420,00026,414,656Sep 02 04:25 PM
Joice Judy RSr. VP Operations & Corp QAJun 03Option Exercise0.7857,82045,10067,611Jun 05 08:33 PM
Joice Judy RSr. VP Operations & Corp QAJun 03Sale2.4557,820141,76332,747Jun 05 08:33 PM
Bleichroeder LP10% OwnerMay 26Sale2.5039,38898,52526,664,656May 28 06:29 PM